Propanc Biopharma, Inc. Logo

Propanc Biopharma, Inc.

Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.

PPCB | NDAQ

Overview

Corporate Details

ISIN(s):
US74346N4043
LEI:
Country:
United States of America
Address:
302/6 BUTLER STREET, 3124 CAMBERWELL, VICTORIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in the research and development of novel cancer treatments. The company focuses on preventing the recurrence and metastasis of solid tumors, particularly for patients with pancreatic, ovarian, and colorectal cancers. Its lead product candidate, PRP, is a pancreatic proenzyme formulation designed to suppress tumor cell migration, inhibit blood vessel formation within tumors, and induce cancer cell death. Propanc's goal is to develop an effective and well-tolerated therapy suitable for long-term, chronic use in cancer management.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Propanc Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Propanc Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Propanc Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.